BCMA/CD19 dual-targeting CAR T cell therapy in older patients with newly diagnosed multiple myeloma: A phase I study

This phase I study evaluated AZD0120, a dual-targeting BCMA/CD19 CAR T therapy, as a frontline treatment for newly diagnosed multiple myeloma patients aged ≥70. Results showed a 100% stringent complete response and MRD negativity rate at one month. The therapy demonstrated a manageable safety profile with no ICANS and only low-grade CRS.